Protein Potential
Protein Potential
Protein Potential

Press & Publications

Press Releases

  • June 15, 2017: Protein Potential, LLC Publishes on its Anthrax and Shigellosis Vaccines Based on Oral Typhoid Fever Vaccine Platform
  • September 25, 2012: Protein Potential, LLC Awarded $1.8 Million to Develop Multi-Component New Malaria Vaccine Solution
  • September 19, 2012: Protein Potential, LLC and Aduro Biotech Inc. awarded Phase 1 SBIR to develop two novel malaria vaccines
  • April 20, 2010: Protein Potential, LLC Awarded $3 Million U.S. NIH Phase II Small Business Innovation Research Grant
  • August 29, 2009: Potential New Treatment for Avian Influenza

Editorials

  • Avian Influenza: Exploring All the Avenues
  • Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?

Grants, Awards and Collaborations

  • 2015-2017 - Principal Investigator - NIH/Small Business Innovation Research Grant (1R43AI106158-01) for Live Attenuated Oral Typhoid-Shigellosis Vaccine
  • 2012-2017 - Principal Investigator - R01 Partnerships for Biodefense (1 R01 AI098884-01) for Development of Enabling Vector/Antigen Expression Technology for an Orally Delivered Multivalent Vaccine for Simultaneous Anthrax-Plague Prophylaxis
  • 2012-2014 - Principal Investigator - NIH/Small Business Innovation Research Grant (1R43AI100531-01) for Multi-stage Multi-antigen Vaccine for Interrupting Malaria Transmission
  • 2012-2014 - Principal Investigator - NIH/Small Business Innovation Research Grant (1R43AI098151-01) for Immunizing Against Malaria by Inducing Both Protective Antibodies and CD8 T Cells
  • 2012-2014 - Principal Investigator - NIH/Small Business Innovation Research Grant (1R43AI096632-01A1) for Multi-Ligand Merozoite Invasion Blocking Malaria Vaccine
  • 2010-2013 - Principal Investigator - NIH/Small Business Innovation Research Grant (2-R44-AI058373-03A2) for Plasmodium vivax Recombinant CS Protein Vaccine for Malaria
  • 2010-2012 - Principal Investigator - NIH/Small Business Innovation Research Grant (1R43AI091273-01) for Live Attenuated Oral Anthrax Vaccine
  • 2008-2010 - Principal Investigator - NIH/Small Business Innovation Research Grant (1-R43-AI077260-01A1) for Recombinant Plasmodium falciparum CelTOS Vaccine
  • 2005-2007 - Principal Investigator - OSD/Small Business Innovation Research Grant Phase II (Ser 341/037) for Production of purified recombinant proteins for development of vaccines of military importance
  • 2005-2007 - Principal Investigator - NIH/Small Business Innovation Research Grant –(1-R43-AI058373-01) for Plasmodium vivax Recombinant CS Protein Vaccine
  • 2007-2009 - Principal Investigator - Program for Appropriate Technology in Health (PATH) and Sanaria Inc. for Attenuated Sporozoite Malaria Vaccine
  • 2004-2006 - Principal Investigator - NIH/Small Business Innovation Research Grant (1-R43-AI058622-01) for A Tetravalent Dengue Recombinant Protein Vaccine
  • 2004-2006 - Principal Investigator - NIH/Small Business Innovation Research Grant (1-R43-AI060098-01) for A SARS-CoV Spike Protein Vaccine

 

Copyright © 2017 Protein Potential, LLC - All rights reserved

Denver web designer